Is BioCryst Pharmaceuticals Inc (BCRX) overvalued? · rev $374.7M
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether BioCryst Pharmaceuticals Inc (BCRX) looks expensive on cached numbers — not a short thesis.
Latest reported BCRX revenue for 2026-06-30 was $374.7M. Net income was -$643.4M. BCRX currently screens at market cap $1.83B.
BCRX currently screens at market cap $1.83B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BCRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BCRX stock page for the full model, not this heading.
Not investment advice.